Literature DB >> 20350992

Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment.

Paolo Alboni1, Giovanni L Botto, Giuseppe Boriani, Giovanni Russo, Federico Pacchioni, Matteo Iori, Giovanni Pasanisi, Marina Mancini, Barbara Mariconti, Alessandro Capucci.   

Abstract

BACKGROUND: Pill-in-the-pocket treatment should be prescribed only if the administration of a loading oral dose of flecainide or propafenone has been proved safe in hospital, since major adverse effects have been reported in 5% of patients during in-hospital treatment. However, in emergency rooms, the oral administration of these drugs for the conversion of atrial fibrillation (AF) is very rarely used because it is time consuming. Objective To investigate whether tolerance to intravenous administration of flecainide or propafenone might predict the safety of pill-in-the-pocket treatment-the out-of-hospital self-administration of these drugs after the onset of palpitations-in patients with AF of recent onset.
METHODS: One hundred and twenty-two patients with AF of recent onset who were successfully treated (conversion of AF within 2 h without major adverse effects) in hospital with intravenous flecainide or propafenone were discharged on pill-in-the-pocket treatment.
RESULTS: During a mean follow-up of 11+/-4 months, 79 patients self-treated 213 arrhythmic episodes; treatment was successful in 201 episodes (94%). Major adverse events occurred in five patients (6%) and in four (5%) of these during the first oral treatment (one syncope, two presyncope, one sinus arrest). No patient reported symptoms attributable to bradyarrhythmia or hypotension during the self-treatment of arrhythmic recurrences when the first oral treatment was not accompanied by any major adverse effects. The study was prematurely terminated because of the high incidence of major adverse effects during the first out-of-hospital treatment.
CONCLUSION: The patient's tolerance of intravenous administration of flecainide or propafenone does not seem to predict adverse effects during out-of-hospital self-administration of these drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20350992     DOI: 10.1136/hrt.2009.187963

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  7 in total

Review 1.  Safety of flecainide.

Authors:  Juan Tamargo; Alessandro Capucci; Philippe Mabo
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

Review 2.  Prophylactic Antiarrhythmic Drug Therapy in Atrial Fibrillation.

Authors:  Moisés Rodríguez-Mañero; Andrea Sarkozy; Gian-Battista Chierchia; Rubén Casado-Arroyo; Danilo Ricciardi; Carlo de Asmundis; Andrea Carlo de; Pedro Sarkozy
Journal:  J Atr Fibrillation       Date:  2013-02-12

Review 3.  Flecainide: Current status and perspectives in arrhythmia management.

Authors:  George K Andrikopoulos; Sokratis Pastromas; Stylianos Tzeis
Journal:  World J Cardiol       Date:  2015-02-26

4.  Cytochrome P450-2D6 Genotype Definition May Improve Therapy for Paroxysmal Atrial Fibrillation A Case of Syncope Following "Pill-in-the-Pocket" Quinidine plus Propafenone.

Authors:  Harry W Daniell M D
Journal:  J Atr Fibrillation       Date:  2014-02-28

Review 5.  Evaluating the benefits of home-based management of atrial fibrillation: current perspectives.

Authors:  Azfar B Sheikh; Jamie R Felzer; Abdullah Bin Munir; Daniel P Morin; Carl J Lavie
Journal:  Pragmat Obs Res       Date:  2016-10-13

6.  Clinical implications from the European Heart Rhythm Association consensus document on antiarrhythmic drug therapy.

Authors:  Emin Evren Özcan; Bülent Görenek
Journal:  Anatol J Cardiol       Date:  2018-07       Impact factor: 1.596

Review 7.  Pulmonary Delivery of Antiarrhythmic Drugs for Rapid Conversion of New-Onset Atrial Fibrillation.

Authors:  Richard L Verrier; Luiz Belardinelli
Journal:  J Cardiovasc Pharmacol       Date:  2020-04       Impact factor: 3.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.